Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].

Zhonghua zhong liu za zhi [Chinese journal of oncology] - 23 Dec 2019

Zhou M, Chen D M, Xia L, Song Y Y, Shi Y K, Yang Z M

Abstract excerpt

Lung cancer is the most frequently diagnosed cancer and the most common cause of cancer mortality in China. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancers. The mutation rate of epidermal growth factor receptor (EGFR) gene is relatively high, accounts for 32%~38% of all NSCLC. During the last decade, the application of EGFR specific tyrosine kinase inhibitors (TKI) significantly improved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 31874554
DOI: 10.3760/cma.j.issn.0253-3766.2019.12.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].PMID 31874554Read ↗

[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor].Semantic proximity Read ↗

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

[Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].Semantic proximity Read ↗

Status and progress of Icotinib in treatment of EGFR-mutant non-small cell lung carcinomaSemantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

[Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China].Semantic proximity Read ↗

[The Diagnosis and Treatment Guideline of Chinese Patients with EGFR Mutation and ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2013 Version)].Semantic proximity Read ↗

[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Application strategies of the third-generation EGFR-TKI in the context of precision medicine].Semantic proximity Read ↗

[Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations].Semantic proximity Read ↗

Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials.Semantic proximity Read ↗

[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.